An infographic exploring the pathophysiology of prurigo nodularis and the role of type 2 inflammation.
Professor Matthias Augustin details the various clinical manifestations of prurigo nodularis, illustrating how different lesion types can present concurrently in patients.
Professor Sarina Elmariah highlights the multifaceted role of IL-4 and IL-13 in driving dermal fibrosis in prurigo nodularis, which leads to persistent scarring and dyspigmentation that significantly contribute to patients' embarrassment, anxiety, depression, and self-esteem.
Professor Matthias Augustin highlights the high prevalence of both atopic and non-atopic comorbidities in patients with PN, including increased risks of cardiovascular events and all-cause mortality.
This is the full presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida, presenting the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).
Explore the clinical features, complex burden, and underlying mechanisms of PN.
Join the effort to improve CRSwNP care. World Anosmia Day serves as an opportunity to raise awareness about the loss of the sense of smell. Access some of countless educational resources with ADVENT below.

This full video presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida features Dr. Eric Simpson, Dr. Shawn Kwatra, Dr. Jason Hawkes and Dr. Victoria Werth. The faculty present the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).
Dr. Sarina Elmariah explains the importance of neuroimmune crosstalk in the development of prurigo nodularis.
In this episode, Dr. Sarina Elmariah and Dr. Brian Kim explore prurigo nodularis (PN), with a focus on severe itch, fibrotic skin lesions, and their impact on patients’ quality of life. They discuss PN epidemiology, common comorbidities, and the challenges of managing multimorbid patients, while breaking down the neuroimmune mechanisms, highlighting the role of type 2 cytokines in itch and lesion development.

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.

Dr. Stephanie Christenson discusses the association between COPD exacerbations and the increased risks of morbidity and mortality